Eclitasertib
| CAS No. | 2125450-76-0 | Cat. No. | BCP48186 |
| Name | Eclitasertib | ||
| Synonyms | Eclitasertibum; | ||
| Formula | C19H18N6O3 | M. Wt | 378.39 |
| Description | Eclitasertib is an orally bioavailable, small-molecule inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1; receptor-interacting protein 1; RIP1), with potential anti-inflammatory and immunomodulatory activities. Upon oral administration, eclitasertib disrupts RIPK1-mediated signaling, and may attenuate inflammation and the resulting tissue damage. RIPK1, a signaling protein in the tumor necrosis factor (TNF) receptor pathway, plays a key role in inflammation and cell death in response to tissue damage and pathogen recognition. | ||
| Pathways | Apoptosis Pathway | ||
| Targets | RIP | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.